Filer Snapshot

PERCEPTIVE ADVISORS LLC

CIK 0001224962. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

232

Latest filing

14 Aug 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q2 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13F portfolio Save page

Largest parsed holding

PRAX

$681.63M reported value

Open holding

13D/G large stake

BlossomHill Therapeutics, Inc.

07 Aug 2026 · 5.9% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13G filed on 14 Aug 2026 for CIK 0001224962.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$6.44B

Quarterly institutional holdings reported on Form 13F; not total AUM.

Forms 3/4/5 positions$1.13B

Reporting-owner positions with enough filing detail to estimate value.

Latest reported 13F value

13F
$6.44B

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Forms 3/4/5 position value

3/4/5
$1.13B

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest 13F holdings

13F
PRAX SYRE CELC ASND RYTM
+15 moreROIV RLAY TVTX KARD NUVL EWTX APGE AMLX MGTX ORKA INBX PTGX SLDB ZYME TNGX

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

CRNX VBIV PCSC SLNO IMTX MGTX ALBO ATXS
+12 moreADMA VRCA ALDX OBIO AGRX LONA CRGX ACRV ADGM RAIN ISO CEMI

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

PRAX SYRE CELC ASND RYTM ROIV RLAY TVTX
+12 moreKARD NUVL EWTX APGE AMLX MGTX ORKA INBX PTGX SLDB ZYME TNGX

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

TRIB SLDB MGTX ATXS NAUT ATHA
+2 moreLYRA Kardigan, Inc.

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

VRNA PRAX SYRE CELC RYTM RLAY
+14 moreACLX FOLD INBX AMLX TVTX ANRO ZYME EWTX AORT IOVA EOLS ENGN IRD CTMX
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
51 Astor Place, 10 Th Floor, New York, NY, 10003
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
DE
Fiscal year end
31 December

Filer intelligence

What SEC filings say about PERCEPTIVE ADVISORS LLC

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Open 13F portfolio Save filer

Quick read

  • Latest parsed 13F shows $6.44B across 102 reported holdings for Q2 2026.
  • Largest parsed 13F holding: PRAX at $681.63M.
  • 5 recent 13D/G stake rows found; top row is BlossomHill Therapeutics, Inc. at 5.9% ownership.
  • Forms 3/4/5 show insider context for CRNX worth $200.34M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 102 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 5 rows

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q2 2026 - 14 Aug 2026

Top 5 concentration

31%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$2B

Compared with $6.44B total 13F value.

Top 5 net change

+$388.92M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: ASND · Largest trim: ASND

PRAX SYRE CELC ASND RYTM Other holdings

PRAX

10.6%

Praxis Precision Medicines I

$681.63M

SYRE

6%

Spyre Therapeutics Inc

$383.48M

CELC

5.2%

Celcuity Inc

$334.49M

ASND

4.8%

Ascendis Pharma A/S

$310.39M

RYTM

4.5%

Rhythm Pharmaceuticals Inc

$287.16M

13D/G large-stake context

BlossomHill Therapeutics, Inc.

07 Aug 2026 · Common Stock, par value $0.0001

5.9%
Issuer page 13D/G history

Yarrow Bioscience, Inc.

27 Jul 2026 · Common Stock, $0.0001 par value

10%
Issuer page 13D/G history

Freenome, Inc.

20 Jul 2026 · Common Stock, par value $0.0001 per share

10%
Issuer page 13D/G history

Research Alliance Corporation IV

13 Jul 2026 · Class A Ordinary Shares, par value $0.0001 per share

7.7%
Issuer page 13D/G history

Forms 3/4/5 insider context

CRNX

18 Apr 2022 · 10% owner

$200.34M
Issuer page Owner page

VBIV

04 Apr 2023 · 10% owner

$137.17M
Issuer page Owner page

PCSC

20 Jul 2026 · 10% owner

$117.06M
Issuer page Owner page

SLNO

26 Sep 2023 · 10% owner

$112.18M
Issuer page Owner page

Latest update

What changed recently for PERCEPTIVE ADVISORS LLC

New filing available

Latest Schedule 13D/G period: 07 Aug 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

14 Aug 2026

Page type

Filer profile

Latest period

07 Aug 2026

Schedule 13D/G context is visible from filings filed on 14 Aug 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

PERCEPTIVE ADVISORS LLC has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest Schedule 13D/G period: 07 Aug 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001224962 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
232
First seen
14 Feb 2014
Latest filing
14 Aug 2026
Entity
Company

Observed form types

13F-HR 13F-HR/A 3 4 SCHEDULE 13D SCHEDULE 13D/A SCHEDULE 13G SCHEDULE 13G/A

CIK-linked evidence first

PERCEPTIVE ADVISORS LLC SEC filings PERCEPTIVE ADVISORS LLC 13F portfolio PERCEPTIVE ADVISORS LLC 13D/G history PERCEPTIVE ADVISORS LLC owner filings Open SEC filing index

Latest Filings

Showing the latest 12 of 232 SEC filings for PERCEPTIVE ADVISORS LLC.

Open full filing history
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .